FLT3 inhibitors for treating Acute Myeloid Leukemia

Acute myelogenous leukemia (AML) is a clonal disorder of hematopoietic stem cells caused by acquired and occasionally inherited genetic alterations(1). FLT3 is a tyrosine kinase receptor that plays a role in proliferation and differentiation of hematopoietic stem cells. Constitutive activation of FLT3 by internal tandem duplication (ITD) mutation is a common molecular alteration in AML, occurring in approximately 20% to 30% of AML patients who have a comparatively poor clinical outcome and increased relapse rate(2).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research